Our Leadership
NewzenPharma’s leadership team is composed of industry experts with a shared dedication to revolutionizing cancer treatment. With deep expertise in clinical development, drug discovery, and regulatory science, our leaders drive innovation through groundbreaking therapies and strategic partnerships. Focused on improving patient outcomes and quality of life, our team is committed to setting new standards in targeted, patient-centered cancer care worldwide.
Vishwas Bhatia, Ph.D.
Chief Executive Officer
Dr. Vishwas Bhatia is a distinguished biotech leader with extensive experience in clinical development, analytical research, and drug discovery across immunology, oncology, and advanced biologics. As CEO of NewzenPharma, he spearheads the company’s mission to innovate prostate cancer treatments through groundbreaking, targeted therapies. Dr. Bhatia’s diverse background spans molecular biology, assay development, regulatory compliance, and large-scale clinical trials, making him a pivotal figure in the advancement of patient-centered cancer care. His leadership drives NewzenPharma’s commitment to improving quality of life for patients globally through science and strategic partnerships.
Shilpa Kadam, Ph.D.
Chief Scientific Officer
Dr. Shilpa Kadam brings over 19 years of expertise in Translational Medicine, focusing on Immuno-Oncology, Oncology, and Non-Oncology drug development. As NewzenPharma’s CSO, she leads innovative strategies in biomarker discovery and companion diagnostics, driving clinical translation and impactful therapies for prostate cancer and beyond. Her industry experience and dedication to groundbreaking early development support NewzenPharma’s commitment to advancing targeted cancer treatments that improve patient outcomes globally.
Nirmal Paliwal, Ph.D.
Chief Technology Officer
Dr. Nirmal Paliwal, CTO of NewzenPharma, brings over 12 years of specialized experience in CMC, Analytical, and Formulation Development within the biopharmaceutical industry. A proven leader in analytical method development and formulation science, Dr. Paliwal has expertly led teams to develop and scale processes for biologics and vaccines, ensuring high standards of quality and compliance. His comprehensive expertise spans analytical and stability testing, method qualifications, and technology transfers, optimizing resources and meeting rigorous clinical and regulatory milestones. As CTO, Dr. Paliwal directs NewzenPharma’s technology strategy, driving advancements in drug formulation and analytical innovations to improve patient outcomes.
Hanief Shajee, Ph.D.
Head of Analytical Research and Development
The Head of Analytical Research and Development at NewzenPharma is responsible for advancing our innovative pipeline through rigorous analytical strategies, from discovery to commercialization. This role ensures the development and validation of cutting-edge bioanalytical methods to support CMC processes, encompassing potency and binding assays, protein characterization, and phase-appropriate regulatory alignment. With a focus on method development, sample testing, data interpretation, and technology transfer, the team leads a full-spectrum approach to ensure the highest quality and regulatory standards in drug development.
Tong Yang
Head of Program Management
Our Head of Program Management brings deep experience in leading cross-functional teams through early and late-phase drug development. With a track record in progressing discovery assets into the clinic, He oversees NewzenPharma’s program/portfolio management and collaboration initiatives. This role is key to aligning cross-functional teams and maintaining focus on NewzenPharma’s corporate objectives.